The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease
about
Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer diseaseBACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor proteinHeparan sulfate proteoglycan induces the production of NO and TNF-alpha by murine microglia.Historical and Current Concepts of Fibrillogenesis and In vivo Amyloidogenesis: Implications of Amyloid Tissue TargetingIn Sickness and in Health: Perineuronal Nets and Synaptic Plasticity in Psychiatric DisordersTowards understanding the roles of heparan sulfate proteoglycans in Alzheimer's diseasePrion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic targetLegal but lethal: functional protein aggregation at the verge of toxicityInflammation and Alzheimer's diseaseA computational approach for identifying the chemical factors involved in the glycosaminoglycans-mediated acceleration of amyloid fibril formationAgrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchymaDifferent configurational states of beta-amyloid and their distributions relative to plaques and tangles in Alzheimer diseaseHeparan sulfate accumulation with Abeta deposits in Alzheimer's disease and Tg2576 mice is contributed by glial cells.Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer's disease.Chondroitin sulphate proteoglycans: preventing plasticity or protecting the CNS?Frontiers in the pathogenesis of Alzheimer's disease.Heparin nanoparticles for β amyloid binding and mitigation of β amyloid associated cytotoxicity.Suppression of amyloid beta A11 antibody immunoreactivity by vitamin C: possible role of heparan sulfate oligosaccharides derived from glypican-1 by ascorbate-induced, nitric oxide (NO)-catalyzed degradation.Changes in brain β-amyloid deposition and aquaporin 4 levels in response to altered agrin expression in miceButyrylcholinesterase is associated with β-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer diseaseProminent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons.Selective binding of soluble Abeta1-40 and Abeta1-42 to a subset of senile plaques.In Alzheimer's disease the Golgi apparatus of a population of neurons without neurofibrillary tangles is fragmented and atrophic.Expression and distribution of amyloid precursor protein-like protein-2 in Alzheimer's disease and in normal brainAgrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain.Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells.Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome.Accumulation of intercellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease.Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain.Cellular interaction and cytotoxicity of the iowa mutation of apolipoprotein A-I (ApoA-IIowa) amyloid mediated by sulfate moieties of heparan sulfate.Amyloid beta-protein as a substrate interacts with extracellular matrix to promote neurite outgrowthSignaling pathways regulating neuron-glia interaction and their implications in Alzheimer's disease.Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid.Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease.Brain extracellular matrix in neurodegeneration.Effects of injected Alzheimer beta-amyloid cores in rat brain.Alzheimer's disease--neuropathological aspects.Susceptibility to neurofibrillary tangles: role of the PTPRD locus and limited pleiotropy with other neuropathologies.Inhibitors of myelination: ECM changes, CSPGs and PTPs.Purification and characterization of heparan sulphate proteoglycan from bovine brain.
P2860
Q24321355-19A15AAD-57FA-4DFD-AA75-6AD215138231Q24675964-04AE4DB2-8B28-4606-BD76-EA4BAC661E42Q24813947-7ADD814E-4E68-42E4-9C3B-D1EA1FA8DC0EQ26744469-79C62B70-AFF5-4AF7-83EA-98B0E488D08DQ26769948-B9530D8D-1443-4AB5-969A-14A522B80BD7Q26992202-1F3BFBB1-0485-415A-B37C-431BA7F2CA9AQ27021159-073D754A-3932-4431-B39A-E7F81C3B5298Q28084859-0E5CB5B8-8189-4844-8287-2737ADF9A1F4Q28138617-A379D5FD-5551-4859-BD8D-F0DB663B3143Q28474733-8EF896D7-08B5-4EA8-9067-5BBE6347F968Q28645584-9ED3BAD0-3B27-466F-8C98-8E2FC5E7832FQ33593817-BA7C955B-CA66-4BC5-BCD7-7AA5F9B46390Q33795144-903CB83E-E719-4EFA-8A15-4E87EB070A11Q33908201-313B4AA3-F852-43B0-B7A0-D288D6133E33Q34285595-480DD60E-5095-4EBA-9580-2A7C03016395Q34572020-DAB9646D-7449-4FE2-9A5F-2AD98617CE09Q35040469-29AC5EFD-504D-4C08-B991-EFE6BFC494C1Q35144959-5FE3ECC9-8F44-431A-846F-8F58F11221FCQ35571874-B8E3F34B-9210-4CC0-A70F-1C3D02E6979DQ35634147-25CCD03E-FFAE-4ECB-B6BA-C66F9B2E26FDQ35745836-199F8FC7-BE09-415C-ACDC-47E1F9B0BDE3Q35774013-26FB526B-4C44-423D-B86F-E85400F1D09CQ35774208-2FC31631-C02C-4808-BE32-B85F630624FEQ35782137-0899AED0-B986-4FD5-B93D-00D8AEE1AF52Q35787956-73C3D1B2-AC94-4D32-B5DD-2F65F7028B89Q35811776-1291CED2-B826-4052-B8EB-ABE33A95B87AQ35811925-824CBD01-995D-42EA-ACAE-F8699EE0E7C8Q35833354-3B04D1E0-A567-4017-B30B-16B78FF7642DQ35833402-0060C8B8-06F2-4061-8E7C-3CC1045400FBQ36115813-7E5E2E69-7610-491C-BACD-2F837D2BE25FQ36317817-B631E309-00BE-4750-AF4E-C3029649303AQ36483870-2DF913D5-5622-4A1C-A968-6C59F0337343Q36707976-93F48A5A-5F16-45D9-BB95-D5315B2385A2Q36961152-809E28C6-ACF0-4A5D-B1D7-3864757D10A5Q37228777-37324A2A-9114-48A9-89DF-AA9F8AA72794Q37596908-E9EDA504-7E79-4B56-BABB-99B5AC32EB7CQ38145154-0303CE4C-A804-43B7-8A85-B2D6B0C91303Q38891507-692631D3-0FBF-404E-9489-7A1D69ADA7E8Q40804371-D548DE2A-1F6B-44F3-BD7A-B8F9999EA9CBQ41816253-F4A8854A-B644-49AB-8B60-2F05C9255D16
P2860
The presence of heparan sulfate proteoglycans in the neuritic plaques and congophilic angiopathy in Alzheimer's disease
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh
1988年學術文章
@zh-hant
name
The presence of heparan sulfat ...... iopathy in Alzheimer's disease
@ast
The presence of heparan sulfat ...... iopathy in Alzheimer's disease
@en
type
label
The presence of heparan sulfat ...... iopathy in Alzheimer's disease
@ast
The presence of heparan sulfat ...... iopathy in Alzheimer's disease
@en
prefLabel
The presence of heparan sulfat ...... iopathy in Alzheimer's disease
@ast
The presence of heparan sulfat ...... iopathy in Alzheimer's disease
@en
P2093
P2860
P1476
The presence of heparan sulfat ...... iopathy in Alzheimer's disease
@en
P2093
P2860
P304
P407
P577
1988-12-01T00:00:00Z